Middle East IVD Market to be Worth $2.15 Billion by 2031

Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) - Forecast to 2031

Meticulous Research^®, a leading global market research company, published a research report titled, ‘Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) - Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the Middle East In Vitro Diagnostics (IVD) market is expected to reach $2.15 billion by 2031 at a CAGR of 4.1% from 2024 to 2031. The growth of the Middle East IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising healthcare expenditures, growth in the aging population, and rising awareness about healthcare. However, high prices for IVD tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market.

The rising awareness regarding early disease diagnosis and increasing inclination toward personalized medicine in the UAE and Saudi Arabia are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.

Key Players

The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy).

Middle East IVD Market: Future Outlook

The Middle East IVD market is segmented by Offering (Kits & Reagents, Instruments, and Software & Services), Technology (Immunoassay/Immunochemistry, Biochemistry/Clinical Chemistry, Molecular Diagnostics, Point of Care (POC) Diagnostics, Whole Blood Glucose Monitoring, Microbiology, Hematology, Coagulation/Hemostasis, Urinalysis, and Other Technologies), Application (Infectious Diseases, Oncology, Diabetes, Cardiology, Nephrology, Autoimmune Disorders, and Other Applications), Diagnostic Approach (Lab Testing, OTC/Self-testing, and Point of Care Testing), and End User (Diagnostic Laboratories, Hospitals & Clinics, Home Healthcare, and Other End Users), and Countries. The study also evaluates industry competitors and analyzes their market share at the country level.

Among all offerings studied in this report, the kits & reagents segment is expected to register the highest CAGR over the forecast period. The highest CAGR of this segment is attributed to the frequent use of reagents and kits in the detection of various chronic and infectious diseases, the wide commercial availability of a diverse range of reagents and consumables for the diagnosis of various diseases, the increase in the volume of testing for infectious diseases such as HIV and influenza, and the growing awareness about self-testing among the general population. According to UNAIDS, global HIV prevalence is decreasing, but the Middle East and North Africa are one of the few regions where new HIV infections are increasing at a rapid rate. In 2022, only 67% of people living with HIV knew their HIV-positive status.

Among all technologies studied in this report, in 2024, the molecular diagnostic segment is expected to account for the largest share of the Middle East IVD market. The large market share of this segment is attributed to the high prevalence of communicable and non-communicable diseases requiring molecular diagnostics (molecular diagnostic tests give more access to high-volume testing in less time and better specificity) and increasing the adoption of molecular diagnostic techniques in hospitals and laboratories.

Among all applications studied in this report, in 2024, the infectious disease segment is expected to account for the largest share of the Middle East IVD market. Infectious diseases are further categorized into respiratory infections (excluding influenza), hepatitis, HIV, HAIs, tropical diseases, influenza, sexually transmitted diseases (STDs), and other infectious diseases. The increasing prevalence of seasonal influenza and sexually transmitted diseases (STDs) is increasing the demand for IVD testing. For instance, people aged over 65 years account for approximately 50-70% of hospitalizations & 90% of influenza-related deaths.

Among all diagnostic approaches studied in this report, the point-of-care testing segment is expected to grow at the highest CAGR during the forecast period. The growth of the POC testing segment is attributed to the increasing prevalence of chronic diseases, the launch of PoC tests by market players, and the lack of skilled technicians for performing lab tests. Additionally, the launch of PoC testing in the region is contributing to the growth of this segment.

Among all end users studied in this report, in 2024, the hospitals & clinics segment is expected to account for the largest share of the Middle East IVD market. Hospitals and clinics perform a wide range of tests to diagnose various medical conditions, including communicable and non-communicable diseases. Hospitals in urban and rural areas provide large populations with access to diagnosis. Also, there was a significant increase in hospital admissions due to a rise in the rate of infectious diseases, which boosted the demand for diagnostic products.

Geographic Review

This research report comprehensively analyzes major countries: Saudi Arabia, UAE, Qatar, Kuwait, Oman, Israel, and the rest of the Middle East. In 2024, Saudi Arabia is expected to account for the largest share of the Middle East IVD market. The largest share of the country is attributed to the growing aging, rising chronic and infectious diseases, and the increasing adoption of self-testing. Additionally, rising healthcare expenditure is increasing the demand for IVD. The healthcare expenditure in Saudi Arabia is rising. The Government of Saudi Arabia has implemented various reforms under the “Vision 2030” strategy to improve the business environment and sectors, including healthcare. Saudi Arabia spent an estimated 6.6% of its GDP on healthcare expenditure in 2021, which is 3.7% higher than the healthcare expenditure a decade ago. Healthcare expenditure in Saudi Arabia is expected to increase at an annual average of 3.0% from 2022 to 2025 to meet “Vision 2030” goals.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5764

Key questions answered in the report:

Which are the high-growth market segments in terms of the offering, technology, application, diagnostic approach, end user, and country?
What was the historical market for IVD testing in the Middle East?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, challenges, and opportunities in the Middle East IVD market?
Who are the major players in the Middle East IVD market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research